Melatonin Vitabalans

Melatonin, the active ingredient in Melatonin Vitabalans, is a melatonin receptor agonist presented as an oral formulation for oral use. It helps regulate the sleep‑wake cycle and is used to manage insomnia and jet‑lag symptoms in adults. By binding to MT1 and MT2 receptors, it promotes sleep onset and supports circadian alignment.

GNH USA supplies Melatonin Vitabalans as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melatonin acts on melatonin receptors to support sleep regulation.

- Insomnia: improves sleep onset and total sleep time in adults. - Jet lag: reduces the time needed to adjust to new time zones. - Circadian rhythm disorder: helps synchronize the internal clock to a normal pattern.

Melatonin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: transient feeling of light‑headedness. - Daytime sleepiness: occasional residual drowsiness. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Allergic reaction: rash, swelling, or difficulty breathing. - Severe dizziness or vertigo. - Mood changes: depression or vivid hallucinations. - Cardiac arrhythmia: irregular heartbeat. - Severe abdominal pain or gastrointestinal bleeding.

Use melatonin with awareness of specific safety considerations.

- Pregnancy: safety not established; consult a healthcare professional before use. - Breastfeeding: unknown effects; exercise caution. - Driving or operating machinery: possible drowsiness; avoid until individual response is known. - Concomitant CNS depressants: may enhance sedative effects. - Underlying medical conditions: use cautiously in epilepsy, depression, or severe liver disease. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Melatonin may interact with other medications; review the following categories.

Major Interactions (Avoid): - Anticoagulants: may increase bleeding risk. - Immunosuppressants: may reduce therapeutic efficacy. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise melatonin plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): additive sedation. - Antidepressants (SSRIs, SNRIs): possible alteration of melatonin metabolism.